No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
JACOS-B (01167.HK) presented initial clinical data on the BET inhibitor JAB-8263 for the treatment of myelofibrosis at the 66th annual conference of hematology in 2024 in the usa.
On December 9, Gelonghui reported that Jianghe Science-B (01167.HK) announced that it showcased preliminary data from a phase I clinical trial of the BET inhibitor JAB-8263 for treating myelofibrosis (MF) at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California, in 2024. The data showed that JAB-8263 has good tolerance, with a recommended dose of 0.3 mg (daily administration) for phase II. The initial efficacy data for JAB-8263 monotherapy for the indication of myelofibrosis is encouraging, with most patients experiencing spleen shrinkage.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Jacobio Pharmaceuticals Completes Dosing for Anti-Cancer Drug Clinical Trial in China
Jaccase (01167) initiated the first clinical study of pan-KRAS inhibitor.
Gilead initiates the first clinical study of pan-KRAS inhibitors.
Jaccoud-B (01167.HK): Goleizase treats pancreatic cancer indications recognized as orphan drug therapies in europe.
On October 21, Gekso-B (01167.HK) announced that the company's independently developed KRAS G12C inhibitor, Glecirasib, has been designated as an orphan drug therapy by the European Medicines Agency for pancreatic cancer. Pancreatic cancer is a highly malignant tumor, with patients currently lacking effective standard treatment options, and a five-year overall survival rate of only 3.1% in advanced pancreatic cancer. Previously, Glecirasib's indication for pancreatic cancer received orphan drug therapy designation from the Food and Drug Administration (FDA) in the USA, and breakthrough therapy designation from the National Medical Products Administration's Center for Drug Evaluation in China.
